EPAS1 and nonpapillary renal cell carcinoma: To test this hypothesis, we treated ccRCC cell lines with hypoxia and observed an additive activation of HIF2α even in the pVHL-inactivated 786-O and OS-RC-2 cell lines, both of which have with abundant constitutive HIF2α (Fig. S2), consistent with previous reports [32, 33].